Pfizer Inc. (NYSE:PFE)‘s stock had its “buy” rating restated by research analysts at Argus in a research report issued to clients and investors on Tuesday. They currently have a $39.00 price target on the biopharmaceutical company’s stock. Argus’ target price points to a potential upside of 15.04% from the stock’s current price.
Several other brokerages have also commented on PFE. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 target price on the stock in a research report on Monday, June 27th. Deutsche Bank AG restated a “buy” rating and set a $44.00 target price on shares of Pfizer in a research report on Thursday, August 18th. Credit Suisse Group AG restated an “outperform” rating and set a $40.00 target price on shares of Pfizer in a research report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on Pfizer and gave the stock a “buy” rating in a research note on Thursday, July 14th. Ten investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $38.78.
Pfizer (NYSE:PFE) opened at 33.90 on Tuesday. Pfizer has a 52 week low of $28.25 and a 52 week high of $37.39. The firm’s 50-day moving average is $34.38 and its 200 day moving average is $34.17. The stock has a market cap of $205.63 billion, a price-to-earnings ratio of 30.05 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. On average, equities research analysts expect that Pfizer will post $2.46 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.54%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
Institutional investors have recently added to or reduced their stakes in the stock. Nelson Roberts Investment Advisors LLC boosted its position in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC acquired a new position in Pfizer during the second quarter valued at approximately $110,000. Tuttle Tactical Management LLC acquired a new position in Pfizer during the second quarter valued at approximately $117,000. Catamount Wealth Management boosted its position in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Finally, Delphi Private Advisors LLC boosted its position in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares during the period. Institutional investors own 69.65% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.